This trial plans to enroll 726 patients across approximately 246 centers in 26 countries, 13 of which are in Europe and 6 in Portugal.
Gastric cancer is the 5th most prevalent cancer worldwide. The aim of this trial is to evaluate the efficacy and safety of an intravenously administered drug in patients with HER2-positive gastric or gastroesophageal junction cancer that is unresectable, locally advanced, or metastatic.
In this group of patients, available therapeutic options are considered limited. Should this study demonstrate positive results, it may contribute to changing clinical practice in this setting and introduce a new therapeutic option that could improve survival rates in patients with advanced gastric cancer.
According to one of the principal investigators, Tânia Rodrigues (Oncology | Hospital da Luz Lisboa): “Clinical trials are essential to drive new treatments and contribute to the advancement of medicine, with a direct impact on people’s lives.”
👉 Regarding ongoing clinical trials at Hospital da Luz: Ensaios clínicos | Learning Health